Description:
Tirzepatide Overview
Tirzepatide is a novel dual agonist of glucagon-like peptide-1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor, administered once weekly. Both GLP-1 and GIP belong to incretins, which are polypeptides secreted by the human gastrointestinal mucosa. GLP-1 can bind to receptors on islet cells, stimulate insulin secretion, thereby lowering blood glucose, and also delay gastric emptying and suppress appetite to control body weight. GIP, on the other hand, functions to inhibit secretion of gastric acid and pepsin, stimulate insulin release, and inhibit gastric peristalsis and emptying, which can complement the effects of GLP-1 receptor agonists. Tirzepatide integrates the insulinotropic effects of the two into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes. The molecule consists of a 39-amino acid peptide backbone and a side chain at residue Lys20. Among the 39 amino acids, 37 are naturally occurring (or encoded), while two are non-natural, namely the non-coding aminoisobutyric acid residues at positions 2 and 13.
Uses
Tirzepatide has a similar sequence to semaglutide, with a PEG-modified lysine side chain that serves as a functional group of the polypeptide and enhances the water solubility of the sequence. As a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide is being developed for the treatment of type 2 diabetes and has entered clinical trials.
Safety Profile
The safety of tirzepatide is similar to that of other incretin-based drugs. A meta-analysis of 7 randomized controlled trials showed that gastrointestinal reactions (such as nausea, diarrhea, and constipation) with tirzepatide were significantly higher than those with placebo, but most were mild to moderate. No significant differences were found between the two groups in other adverse reactions, especially hypoglycemia. However, due to its short time on the market, the actual safety remains to be observed in post-marketing settings.
Efficacy in Glycemic Control and Weight Loss
The SURPASS program is a series of large-scale randomized controlled trials designed to evaluate the efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus (T2DM). Among them, the results of SURPASS-2[1], a head-to-head comparison with semaglutide, are the most encouraging. This study compared the glycemic effects of tirzepatide at doses of 5mg (n=470), 10mg (n=469), and 15mg (n=469) with semaglutide 1mg (n=468). The results showed that compared with the baseline HbA1c level (8.3%), tirzepatide reduced subjects’ average HbA1c by 2.0%, 2.2%, and 2.3%, respectively, while semaglutide reduced it by an average of 1.9%. In terms of weight loss, compared with the baseline weight (207 lbs), tirzepatide reduced subjects’ average weight by 17 lbs, 21 lbs, and 25 lbs, respectively, while semaglutide reduced it by 13 lbs. This trial demonstrated that tirzepatide has superior glycemic control and weight loss capabilities compared to semaglutide. Another large study recruited 2,539 adults with at least one obesity complication (excluding diabetes) and a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m². All subjects were randomly assigned in equal proportions to tirzepatide 5mg, 10mg, 15mg, and placebo groups. The results showed that at week 72, the weight loss in each group was 16.1kg, 22.2kg, 23.6kg, and 2.4kg, respectively[2]. The weight loss effect of tirzepatide is comparable to that of bariatric surgery. Tirzepatide has a similar sequence to semaglutide, with a PEG-modified lysine side chain that acts as a functional group of the polypeptide and improves the water solubility of the sequence. As a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide is being developed for the treatment of type 2 diabetes and has entered clinical trials.
Reference Quality Standards
- Appearance: White powder
- Purity (HPLC): ≥95.0%
- Acetate content: 5.0%～12.0%
- Moisture content: ≤8.0%
- Peptide content: ≥70.0%
- Amino acid composition analysis: ≤±10%
Reviews
There are no reviews yet.